NATCO launches Bosentan Tablets for oral suspension in US with 180-day exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Phase 1 dosing is expected to finish by the end of 2025
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
Subscribe To Our Newsletter & Stay Updated